RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

After months of waiting, a young boy from Cuba battling a medical condition is getting a second chance at life after he and his family received a visa to travel to South Florida for treatment. Damir ...

SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.

Reivi Dela Cruz was only four years old when he was diagnosed with Neurofibromatosis Type 1 (NF1), a genetic condition that causes tumors (neurofibromas, which are usually non-cancerous) to grow on or ...

Over the last 7 days, the United States market has dropped by 4.4%, yet it has risen by 7.5% over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high ...

Rising Demand for Water Treatment Solutions Governments and industries worldwide are increasingly focusing on sustainable ...

Anti-neurofilament L antibodies play a crucial role in detecting and monitoring neurodegenerative diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis ...

Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...